Skip to content
The BCI Briefing

Company profileCore BCI

NeuroXess脑虎科技

Flexible high-channel-count implants, with early human work on movement and Mandarin speech decoding.

Location
Shanghai, China
Class
Core BCI
Also known as
Naohu Keji · NeuroXess Technology (Shanghai) Co., Ltd.
Sources last checked
4 Oct 2026

What they are building

Shanghai company developing flexible, high-throughput brain interfaces; its early human recordings were made in patients undergoing epilepsy or tumour surgery at Huashan Hospital.

Interface category
Electrocorticography
Signal
Local field potentials, including high-gamma activity
Invasiveness
Invasive
Recording / stimulation
Recording
Main use cases
Communicate, Control, Move
Works with
Huashan Hospital, Fudan University

Where they are clinically

Clinical study

A larger structured study of safety and performance, short of a pivotal trial.

The human results reported so far come from short-term implants in patients having surgery for other reasons. A 32-participant study of a fully implanted system for hand function in tetraplegia has been registered as recruiting since July 2026; it has not reported.

Access today

Experimental human research

Demonstrated in a small number of research participants. Not an established treatment.

Shown in people
Short-term recordings in surgical patients: Mandarin decoded at 71% over 142 syllables within five days of implantation, according to news reports.
Still an aim
A fully implanted wireless system for hand function, in a 32-participant study recruiting since July 2026.
What stands in the way
Chronic data: everything reported comes from implants of days, not months.

On record here: 1 registered study · 32 participants planned or enrolled · 0 peer-reviewed papers

This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.

Why this company matters

NeuroXess has reported the first real-time decoding of Mandarin, a tonal language with a syllable inventory unlike English, which makes it a different decoding problem from the one US speech BCIs have solved. The figures come from news reports of short-term recordings in surgical patients, not from a peer-reviewed study, and cannot yet be set beside the published English-language benchmarks. The study it registered in 2026 is a different undertaking: a fully implanted system for hand function, the indication Neuracle's NEO was registered for.

Key milestones

  1. 7 Jul 2026

    A multi-centre, single-arm study of a fully implanted system for hand function in tetraplegia begins recruiting at Huashan Hospital; 32 participants planned.

    Efficacy and safety of an implantable BCI hand motor function compensation system in tetraplegia after spinal cord injury · NCT07720882

  2. Dec 2025

    Company reports the first clinical trial of a fully implanted, wireless, battery-integrated system at Huashan Hospital.

    Pandaily

  3. Dec 2024

    Real-time decoding of Mandarin speech reported in a second patient: 71% accuracy over 142 common syllables within five days of implantation.

    China Daily

  4. Aug 2024

    A 256-channel flexible device is implanted in a patient with epilepsy at Huashan Hospital; real-time decoding of intended movement is reported.

    China Daily

Clinical programmes

Leadership

  • Tao Hu (陶虎)

    Founder and chief scientist

As publicly stated by the organisation. Not a complete list.

IP and patents

Filings touch 5 of the 11 layers, most often interface and electrodes (51 of 65 families) and implant electronics (23).

65
patent families identified and counted as BCI
2020
earliest first filing among them
61
first filed since 2021; the latest years are incomplete
38 of 65
include a granted member, of those whose family record was read

Across the stack: families by layer

Themes, by number of families: electrodes and arrays (51), implant electronics (15), insertion tools and robots (13), neural decoding (13), signal acquisition (11), chips and on-implant computing (9). A family can carry several.

Published in: China (65), United States (1), counted over the 65 families whose full record was read.

Representative families

59 more families counted

Families found for NeuroXess in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this

Competitive context

Latest BCI Briefing coverage

Sources

  1. 01

    Brain-computer interface makes breakthrough by deciphering Chinese speech in brain (opens in a new tab)

    Independent reportingChina Daily3 Jan 2025Checked against source 4 Oct 2026

    State-owned English-language newspaper reporting the company's and hospital's results. No peer-reviewed publication is cited.

  2. 02

    NeuroXess achieves clinical success with its fully implanted, wireless, battery-integrated brain-computer interface (opens in a new tab)

    Company reportedPandailySource identified, not opened

    Identified through search; the article text could not be opened. Reports a company announcement of December 2025.

  3. 03

    ClinicalTrials.gov NCT07720882 (opens in a new tab)

    Clinical registryClinicalTrials.gov22 Jul 2026Checked against source 3 Oct 2026

    Registry record last updated 2026-07-22.